HEALIOS K.K. Logo

HEALIOS K.K.

Develops iPS and somatic stem cell therapies for diseases like ARDS and cancer.

4593 | T

Overview

Corporate Details

ISIN(s):
N/A
LEI:
Country:
Japan
Address:
千代田区有楽町一丁目7番1号
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Healios K.K. is a biotechnology company specializing in the research, development, and manufacturing of cell therapy and regenerative medicine products. A pioneer in the field, the company develops treatments for diseases with high unmet medical needs by leveraging induced pluripotent stem (iPS) cell technology and somatic stem cells. Its core R&D focuses on creating therapies from iPS cell-derived products, including retinal pigment epithelium (RPE) cells and Natural Killer (NK) cells for cancer immunotherapy. The company's pipeline also features somatic stem cell products like HLCM051 (MultiStem) for treating conditions such as acute respiratory distress syndrome (ARDS). Healios utilizes proprietary gene editing technology to develop next-generation universal donor cells, aiming to overcome immune rejection and broaden the application of cellular medicine.

This is a Fraction of the Available Data.

You're viewing a limited, static snapshot. Professionals use our API to get real-time, AI-ready data for HEALIOS K.K. and 9,000+ other companies.

Stop analyzing yesterday's news. Start building a real-time advantage.

Request Enterprise API Access

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Date Filing Language Size Actions
2025-08-13 05:35
Regulatory News Service
確認書
Japanese 8.2 KB
2025-08-13 05:34
Interim Report
半期報告書-第15期(2025/01/01-2025/12/31)
Japanese 436.9 KB
2025-05-13 08:33
Regulatory News Service
臨時報告書
Japanese 19.7 KB
2025-03-27 07:22
Regulatory News Service
臨時報告書
Japanese 25.4 KB
2025-03-27 07:21
Regulatory News Service
確認書
Japanese 8.1 KB
2025-03-27 07:20
Regulatory News Service
内部統制報告書-第14期(2024/01/01-2024/12/31)
Japanese 21.7 KB
2025-03-27 07:19
Annual Report
有価証券報告書-第14期(2024/01/01-2024/12/31)
Japanese 2.0 MB
2025-02-14 05:13
Regulatory News Service
訂正臨時報告書
Japanese 37.5 KB
2025-02-14 04:07
Regulatory News Service
臨時報告書
Japanese 21.3 KB
2025-01-27 07:31
Prospectus
有価証券届出書(参照方式)
Japanese 224.3 KB
2025-01-22 07:33
Regulatory News Service
臨時報告書
Japanese 53.3 KB
2024-11-13 07:34
Regulatory News Service
臨時報告書
Japanese 20.0 KB
2024-08-13 08:04
Regulatory News Service
臨時報告書
Japanese 19.9 KB
2024-08-13 08:04
Regulatory News Service
確認書
Japanese 8.2 KB
2024-08-13 08:03
Interim Report
半期報告書-第14期(2024/01/01-2024/12/31)
Japanese 402.0 KB

Automate Your Workflow. Get a real-time feed of all HEALIOS K.K. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for HEALIOS K.K. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
HEMOGENYX PHARMACEUTICALS PLC Logo
Develops CAR-T therapies for blood cancers, autoimmune disorders, and viral infections.
United Kingdom HEMO
Hemp Health Spolka Akcyjna Logo
A vertically integrated supplier of medical cannabis raw material for the Polish market.
Poland HMP
Herantis Pharma Oyj Logo
Developing disease-modifying therapies for neurodegenerative conditions like Parkinson's disease.
Finland HRTIS
HIKMA Pharmaceuticals PLC Logo
Develops & markets affordable generic & specialty medicines for markets in NA, MENA, & Europe.
United Kingdom HIK
HISAMITSU PHARMACEUTICAL CO.,INC. Logo
A global leader in transdermal drug delivery systems for OTC and prescription pain relief.
Japan 4530
H. Lundbeck A Logo
Develops and commercializes innovative therapeutics for brain diseases globally.
Denmark HLUN
Human Stem Cells Institute PJSC Logo
A biotech investor developing gene therapy, regenerative medicine, and genetic services.
Russian Federation ISKJ
Hong Kong N/A
Hyloris Pharmaceuticals SA Logo
A biopharma company optimizing existing drugs for unmet needs via abbreviated pathways.
Belgium HYL
Idorsia Ltd Logo
Develops and commercializes small-molecule medicines for CNS, cardiovascular, and immune disorders.
Switzerland IDIA

Talk to a Data Expert

Have a question? We'll get back to you promptly.